ÂÜÀòÂÒÂ×

Mr. Harris most recently served as the Chief Financial Officer of MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing therapies for the treatment of serious cardiovascular diseases. MyoKardia was acquired in November 2020 by Bristol Myers Squibb for $13.1 billion. Prior to joining MyoKardia, Mr. Harris served as Chief Financial Officer of Zeltiq Aesthetics, Inc., until that company’s acquisition by Allergan plc. Prior to Zeltiq, Mr. Harris served as Chief Financial Officer at Thoratec Corporation, until that company’s acquisition by St. Jude Medical, Inc. Prior to joining Thoratec, Mr. Harris worked at JPMorgan Chase & Co. for over a decade in several capacities, including as a Vice President in the firm's Healthcare Investment Banking and Equity Research departments. Mr. Harris holds a Bachelor of Arts in Physics and Economics from the University of North Carolina at Chapel Hill, where he studied as a Morehead-Cain Scholar.